Vaxart Inc Valuation
| VXRTDelisted Stock | USD 0.35 0.05 16.67% |
Vaxart seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Vaxart Inc from inspecting the company fundamentals such as Return On Equity of -1.15, shares outstanding of 228.22 M, and Operating Margin of (0.72) % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vaxart's price fluctuation is out of control at this time. Calculation of the real value of Vaxart Inc is based on 3 months time horizon. Increasing Vaxart's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vaxart's intrinsic value may or may not be the same as its current market price of 0.35, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.35 | Real 0.33 | Hype 0.34 | Naive 0.19 |
The intrinsic value of Vaxart's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaxart's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaxart Inc helps investors to forecast how Vaxart stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaxart more accurately as focusing exclusively on Vaxart's fundamentals will not take into account other important factors: Vaxart Total Value Analysis
Vaxart Inc is at this time projected to have valuation of 43.36 M with market capitalization of 73.03 M, debt of 17.53 M, and cash on hands of 129.55 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Vaxart fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
43.36 M | 73.03 M | 17.53 M | 129.55 M |
Vaxart Investor Information
The company has Price to Book (P/B) ratio of 1.5. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vaxart Inc recorded a loss per share of 0.26. The entity last dividend was issued on the 9th of November 2012. The firm had 1:11 split on the 14th of February 2018. Based on the key indicators related to Vaxart's liquidity, profitability, solvency, and operating efficiency, Vaxart Inc is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Vaxart Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vaxart has an asset utilization ratio of 17.25 percent. This implies that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Vaxart Inc is more efficient with each dollar of assets it utilizes for everyday operations.Vaxart Ownership Allocation
Vaxart Inc shows a total of 228.22 Million outstanding shares. About 86.86 % of Vaxart outstanding shares are held by general public with 1.06 (%) owned by insiders and only 12.08 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vaxart Profitability Analysis
The company reported the previous year's revenue of 28.7 M. Net Loss for the year was (66.95 M) with loss before overhead, payroll, taxes, and interest of (38.55 M).About Vaxart Valuation
The delisted stock valuation mechanism determines Vaxart's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vaxart Inc based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vaxart. We calculate exposure to Vaxart's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaxart's related companies.Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
Vaxart Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vaxart does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2 B | |
| Forward Price Earnings | 42.735 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Vaxart Stock
If you are still planning to invest in Vaxart Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaxart's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |